PDF herunterladen
Semin Neurol 2019; 39(02): 264-273
DOI: 10.1055/s-0039-1678584
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Rare Tauopathies

Farwa Ali
1   Department of Neurology, Mayo Clinic, Rochester, Minnesota
,
Keith Josephs
1   Department of Neurology, Mayo Clinic, Rochester, Minnesota
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
29. März 2019 (online)

   Lizenzen und Reprints

Abstract

Tauopathies are rare neurodegenerative disorders related to microtubule-associated protein tau, which functions to stabilize microtubules. Pathological changes caused by overexpression or hyperphosphorylation of tau lead to the disengagement of tau from microtubules and accumulation of toxic intracellular inclusions. Tau pathology is the underlying mechanism for several sporadic and genetic disorders. These are collectively known as tauopathies. Each tauopathy is differentiated from others by its neuropathological features such as the presence of specific isoforms of tau, type of cellular inclusions, and the regions of the brain affected. Neuropathological features, with a few exceptions however, do not correspond to distinct clinical phenotypes. There is considerable phenotypic overlap between the different tauopathies. Interaction between tau and other protein inclusions further alters the clinical phenotype.

Recent advances in the development of tau biomarkers, especially the development of tau radioligands used in positron emission tomography neuroimaging, and a better understanding of biology and pathology of tau are important first steps toward the ultimate goal of accurate diagnosis and disease modification in tauopathies.

Keywords

tau - tau-PET - MAPT - FTLD-tau
 

  • References

  • 1 Josephs KA, Hodges JR, Snowden JS. , et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 2011; 122 (02) 137-153
    CrossrefPubMedGoogle Scholar
  • 2 Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 2015; 41 (01) 3-23
    CrossrefPubMedGoogle Scholar
  • 3 Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 1975; 72 (05) 1858-1862
    CrossrefPubMedGoogle Scholar
  • 4 Kempf M, Clement A, Faissner A, Lee G, Brandt R. Tau binds to the distal axon early in development of polarity in a microtubule- and microfilament-dependent manner. J Neurosci 1996; 16 (18) 5583-5592
    CrossrefPubMedGoogle Scholar
  • 5 Komori T. Pathology of oligodendroglia: an overview. Neuropathology 2017; 37 (05) 465-474
    CrossrefPubMedGoogle Scholar
  • 6 Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989; 8 (02) 393-399
    CrossrefPubMedGoogle Scholar
  • 7 Myers AJ, Pittman AM, Zhao AS. , et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 2007; 25 (03) 561-570
    CrossrefPubMedGoogle Scholar
  • 8 Bodea LG, Eckert A, Ittner LM. . of OPJ. Tau physiology and pathomechanisms in frontotemporal lobar degeneration. Wiley Online Library; 2016
    Google Scholar
  • 9 Gibb GM, de Silva R, Revesz T, Lees AJ, Anderton BH, Hanger DP. Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Brain Res Mol Brain Res 2004; 121 (1-2): 95-101
    CrossrefPubMedGoogle Scholar
  • 10 Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 1984; 259 (08) 5301-5305
    CrossrefPubMedGoogle Scholar
  • 11 Morris M, Knudsen GM, Maeda S. , et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 2015; 18 (08) 1183-1189
    PubMedGoogle Scholar
  • 12 Zhao Y, Tseng I-C, Heyser CJ. , et al. Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. Neuron 2015; 87 (05) 963-975
    CrossrefPubMedGoogle Scholar
  • 13 Zhang C-C, Xing A, Tan M-S, Tan L, Yu J-T. The role of MAPT in neurodegenerative diseases: genetics, mechanisms and therapy. Mol Neurobiol 2016; 53 (07) 4893-4904
    CrossrefPubMedGoogle Scholar
  • 14 Schoch KM, DeVos SL, Miller RL. , et al. Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron 2016; 90 (05) 941-947
    CrossrefPubMedGoogle Scholar
  • 15 Clavaguera F, Akatsu H, Fraser G. , et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 2013; 110 (23) 9535-9540
    CrossrefPubMedGoogle Scholar
  • 16 Maphis N, Xu G, Kokiko-Cochran ON. , et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain 2015; 138 (Pt 6): 1738-1755
    CrossrefPubMedGoogle Scholar
  • 17 Ittner LM, Ke YD, Delerue F. , et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142 (03) 387-397
    CrossrefPubMedGoogle Scholar
  • 18 Gu J, Chen F, Iqbal K, Gong C-X, Wang X, Liu F. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: implications for the pathogenesis of tauopathies. J Biol Chem 2017; 292 (25) 10600-10612
    CrossrefPubMedGoogle Scholar
  • 19 Armstrong MJ, Litvan I, Lang AE. , et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80 (05) 496-503
    CrossrefPubMedGoogle Scholar
  • 20 Höglinger GU, Respondek G, Stamelou M. , et al; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 2017; 32 (06) 853-864
    CrossrefPubMedGoogle Scholar
  • 21 Forrest SL, Kril JJ, Stevens CH. , et al. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain 2018; 141 (02) 521-534
    CrossrefPubMedGoogle Scholar
  • 22 Josephs KA. Rest in peace FTDP-17. Brain 2018; 141 (02) 324-331
    CrossrefPubMedGoogle Scholar
  • 23 Togo T, Sahara N, Yen S-H. , et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 2002; 61 (06) 547-556
    CrossrefPubMedGoogle Scholar
  • 24 Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011; 7 (05) 263-272
    PubMedGoogle Scholar
  • 25 Yokoyama JS, Karch CM, Fan CC. , et al; International FTD-Genomics Consortium (IFGC). Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol 2017; 133 (05) 825-837
    CrossrefPubMedGoogle Scholar
  • 26 Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 2015; 41 (01) 24-46
    CrossrefPubMedGoogle Scholar
  • 27 Tacik P, Sanchez-Contreras M, Rademakers R, Dickson DW, Wszolek ZK. Genetic disorders with tau pathology: a review of the literature and report of two patients with tauopathy and positive family histories. Neurodegener Dis 2016; 16 (1-2): 12-21
    CrossrefPubMedGoogle Scholar
  • 28 Coppola G, Chinnathambi S, Lee JJ. , et al; Alzheimer's Disease Genetics Consortium. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 2012; 21 (15) 3500-3512
    CrossrefPubMedGoogle Scholar
  • 29 Fujioka S, Sanchez Contreras MY, Strongosky AJ. , et al. Three sib-pairs of autopsy-confirmed progressive supranuclear palsy. Parkinsonism Relat Disord 2015; 21 (02) 101-105
    CrossrefPubMedGoogle Scholar
  • 30 Höglinger GU, Melhem NM, Dickson DW. , et al; PSP Genetics Study Group. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43 (07) 699-705
    CrossrefPubMedGoogle Scholar
  • 31 Kouri N, Ross OA, Dombroski B. , et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun 2015; 6: 7247
    CrossrefPubMedGoogle Scholar
  • 32 Wilke C, Pomper JK, Biskup S, Puskás C, Berg D, Synofzik M. Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. J Neurol 2016; 263 (03) 558-574
    CrossrefPubMedGoogle Scholar
  • 33 Gustavsson EK, Trinh J, Guella I. , et al. DCTN1 p.K56R in progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 28 (C): 56-61
    CrossrefPubMedGoogle Scholar
  • 34 Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-359
    CrossrefPubMedGoogle Scholar
  • 35 Hauw JJ, Daniel SE, Dickson D. , et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44 (11) 2015-2019
    CrossrefPubMedGoogle Scholar
  • 36 Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246 (Suppl. 02) II6-II15
    PubMedGoogle Scholar
  • 37 Litvan I, Agid Y, Calne D. , et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 38 Owens E, Josephs KA, Savica R. , et al. The clinical spectrum and natural history of pure akinesia with gait freezing. J Neurol 2016; 263 (12) 2419-2423
    CrossrefPubMedGoogle Scholar
  • 39 Kurz C, Ebersbach G, Respondek G, Giese A, Arzberger T, Höglinger GU. An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability. Acta Neuropathol Commun 2016; 4 (01) 120
    CrossrefPubMedGoogle Scholar
  • 40 Morris HR, Gibb G, Katzenschlager R. , et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 2002; 125 (Pt 5): 969-975
    CrossrefPubMedGoogle Scholar
  • 41 Respondek G, Höglinger GU. The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 22 (Suppl. 01) S34-S36
    CrossrefPubMedGoogle Scholar
  • 42 Respondek G, Stamelou M, Kurz C. , et al; Movement Disorder Society-endorsed PSP Study Group. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29 (14) 1758-1766
    CrossrefPubMedGoogle Scholar
  • 43 Donker Kaat L, Boon AJW, Kamphorst W, Ravid R, Duivenvoorden HJ, van Swieten JC. Frontal presentation in progressive supranuclear palsy. Neurology 2007; 69 (08) 723-729
    CrossrefPubMedGoogle Scholar
  • 44 Josephs KA, Duffy JR, Strand EA. , et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129 (Pt 6): 1385-1398
    CrossrefPubMedGoogle Scholar
  • 45 Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol 2008; 21 (06) 688-692
    CrossrefPubMedGoogle Scholar
  • 46 Josephs KA, Duffy JR, Strand EA. , et al. The evolution of primary progressive apraxia of speech. Brain 2014; 137 (Pt 10): 2783-2795
    CrossrefPubMedGoogle Scholar
  • 47 Respondek G, Kurz C, Arzberger T. , et al; Movement Disorder Society-Endorsed PSP Study Group. Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Mov Disord 2017; 32 (07) 995-1005
    CrossrefPubMedGoogle Scholar
  • 48 Dickson DW, Bergeron C, Chin SS. , et al; Office of Rare Diseases of the National Institutes of Health. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61 (11) 935-946
    CrossrefPubMedGoogle Scholar
  • 49 Ling H, O'Sullivan SS, Holton JL. , et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010; 133 (Pt 7): 2045-2057
    CrossrefPubMedGoogle Scholar
  • 50 Kouri N, Murray ME, Hassan A. , et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 2011; 134 (Pt 11): 3264-3275
    CrossrefPubMedGoogle Scholar
  • 51 Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 2014; 85 (08) 925-929
    CrossrefPubMedGoogle Scholar
  • 52 Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 1998; 43 (02) 193-204
    CrossrefPubMedGoogle Scholar
  • 53 Dickson DW. Neuropathology of Pick's disease. Neurology 2001; 56 (11) (Suppl. 04) S16-S20
    CrossrefPubMedGoogle Scholar
  • 54 Dickson DW. Pick's disease: a modern approach. Brain Pathol 1998; 8 (02) 339-354
    PubMedGoogle Scholar
  • 55 Rankin KP, Mayo MC, Seeley WW. , et al. Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease. J Mol Neurosci 2011; 45 (03) 594-608
    CrossrefPubMedGoogle Scholar
  • 56 Piguet O, Halliday GM, Reid WGJ. , et al. Clinical phenotypes in autopsy-confirmed Pick disease. Neurology 2011; 76 (03) 253-259
    CrossrefPubMedGoogle Scholar
  • 57 Uyama N, Yokochi F, Bandoh M, Mizutani T. Primary progressive apraxia of speech (AOS) in a patient with Pick's disease with Pick bodies: a neuropsychological and anatomical study and review of literatures. Neurocase 2013; 19 (01) 14-21
    CrossrefPubMedGoogle Scholar
  • 58 Ahmed Z, Bigio EH, Budka H. , et al. Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol 2013; 126 (04) 537-544
    CrossrefPubMedGoogle Scholar
  • 59 Josephs KA, Katsuse O, Beccano-Kelly DA. , et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol 2006; 65 (04) 396-405
    CrossrefPubMedGoogle Scholar
  • 60 Kovacs GG, Majtenyi K, Spina S. , et al. White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol 2008; 67 (10) 963-975
    CrossrefPubMedGoogle Scholar
  • 61 Braak H, Braak E. Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett 1987; 76 (01) 124-127
    CrossrefPubMedGoogle Scholar
  • 62 Saito Y, Ruberu NN, Sawabe M. , et al. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 2004; 63 (09) 911-918
    CrossrefPubMedGoogle Scholar
  • 63 Tolnay M, Clavaguera F. Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies. Neuropathology 2004; 24 (04) 269-283
    CrossrefPubMedGoogle Scholar
  • 64 Martinez-Lage P, Munoz DG. Prevalence and disease associations of argyrophilic grains of Braak. J Neuropathol Exp Neurol 1997; 56 (02) 157-164
    CrossrefPubMedGoogle Scholar
  • 65 Josephs KA, Whitwell JL, Parisi JE. , et al. Argyrophilic grains: a distinct disease or an additive pathology?. Neurobiol Aging 2008; 29 (04) 566-573
    CrossrefPubMedGoogle Scholar
  • 66 Crary JF, Trojanowski JQ, Schneider JA. , et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128 (06) 755-766
    CrossrefPubMedGoogle Scholar
  • 67 Janocko NJ, Brodersen KA, Soto-Ortolaza AI. , et al. Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol 2012; 124 (05) 681-692
    CrossrefPubMedGoogle Scholar
  • 68 Josephs KA, Murray ME, Tosakulwong N. , et al. Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol 2017; 133 (05) 705-715
    CrossrefPubMedGoogle Scholar
  • 69 Jellinger KA, Alafuzoff I, Attems J. , et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol 2015; 129 (05) 757-762
    CrossrefPubMedGoogle Scholar
  • 70 Kovacs GG, Ferrer I, Grinberg LT. , et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 2016; 131 (01) 87-102
    CrossrefPubMedGoogle Scholar
  • 71 Kovacs GG, Robinson JL, Xie SX. , et al. Evaluating the patterns of aging-related tau astrogliopathy unravels novel insights into brain aging and neurodegenerative diseases. J Neuropathol Exp Neurol 2017; 76 (04) 270-288
    CrossrefPubMedGoogle Scholar
  • 72 Kovacs GG, Yousef A, Kaindl S, Lee VM, Trojanowski JQ. Connexin-43 and aquaporin-4 are markers of ageing-related tau astrogliopathy (ARTAG)-related astroglial response. Neuropathol Appl Neurobiol 2017; 131: 87-15
    PubMedGoogle Scholar
  • 73 Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82 (04) 239-259
    CrossrefPubMedGoogle Scholar
  • 74 Oikawa T, Nonaka T, Terada M, Tamaoka A, Hisanaga S, Hasegawa M. α-synuclein fibrils exhibit gain of toxic function, promoting tau aggregation and inhibiting microtubule assembly. J Biol Chem 2016; 291 (29) 15046-15056
    CrossrefPubMedGoogle Scholar
  • 75 Distl R, Treiber-Held S, Albert F, Meske V, Harzer K, Ohm TG. Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. J Pathol 2003; 200 (01) 104-111
    CrossrefPubMedGoogle Scholar
  • 76 Li A, Paudel R, Johnson R. , et al. Pantothenate kinase-associated neurodegeneration is not a synucleinopathy. Neuropathol Appl Neurobiol 2013; 39 (02) 121-131
    CrossrefPubMedGoogle Scholar
  • 77 Kapás I, Katkó M, Harangi M. , et al. Cerebrotendinous xanthomatosis with the c.379C>T (p.R127W) mutation in the CYP27A1 gene associated with premature age-associated limbic tauopathy. Neuropathol Appl Neurobiol 2014; 40 (03) 345-350
    CrossrefPubMedGoogle Scholar
  • 78 Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. ; MD GP. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 2012; 11 (07) 618-628
    CrossrefPubMedGoogle Scholar
  • 79 Ikeda K, Akiyama H, Kondo H, Arai T, Arai N, Yagishita S. Numerous glial fibrillary tangles in oligodendroglia in cases of subacute sclerosing panencephalitis with neurofibrillary tangles. Neurosci Lett 1995; 194 (1-2): 133-135
    CrossrefPubMedGoogle Scholar
  • 80 Scherrer VB, Buée L, Leveugle B. , et al. Pathological τ proteins in postencephalitic parkinsonism: Comparison with Alzheimer's disease and other neurodegenerative disorders. Ann Neurol 2004; 42 (03) 356-359
    PubMedGoogle Scholar
  • 81 McKee AC, Stern RA, Nowinski CJ. , et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013; 136 (Pt 1): 43-64
    CrossrefPubMedGoogle Scholar
  • 82 Stein TD, Alvarez VE, McKee AC. Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. Alzheimers Res Ther 2014; 6 (01) 4
    CrossrefPubMedGoogle Scholar
  • 83 McKee AC, Cairns NJ, Dickson DW. , et al; TBI/CTE group. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 2016; 131 (01) 75-86
    CrossrefPubMedGoogle Scholar
  • 84 Rojas JC, Karydas A, Bang J. , et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 2016; 3 (03) 216-225
    CrossrefPubMedGoogle Scholar
  • 85 Scherling CS, Hall T, Berisha F. , et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014; 75 (01) 116-126
    CrossrefPubMedGoogle Scholar
  • 86 Magdalinou NK, Paterson RW, Schott JM. , et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015; 86 (11) 1240-1247
    CrossrefPubMedGoogle Scholar
  • 87 Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M. Decreased β-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2005; 237 (1-2): 61-65
    CrossrefPubMedGoogle Scholar
  • 88 Whitwell JL, Jack Jr CR, Boeve BF. , et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 2010; 75 (21) 1879-1887
    CrossrefPubMedGoogle Scholar
  • 89 Josephs KA, Tang-Wai DF, Edland SD. , et al. Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration. Arch Neurol 2004; 61 (12) 1881-1884
    PubMedGoogle Scholar
  • 90 Mueller C, Hussl A, Krismer F. , et al. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism Relat Disord 2018; 54: 90-94
    CrossrefPubMedGoogle Scholar
  • 91 Whitwell JL, Jack Jr CR, Parisi JE. , et al. Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. Eur J Neurol 2013; 20 (10) 1417-1422
    CrossrefPubMedGoogle Scholar
  • 92 Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol 2005; 4 (11) 771-780
    CrossrefPubMedGoogle Scholar
  • 93 Whitwell JL, Weigand SD, Boeve BF. , et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012; 135 (Pt 3): 794-806
    CrossrefPubMedGoogle Scholar
  • 94 Whitwell JL, Schwarz CG, Reid RI, Kantarci K, Jack Jr CR, Josephs KA. Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord 2014; 20 (05) 493-498
    CrossrefPubMedGoogle Scholar
  • 95 Zalewski N, Botha H, Whitwell JL, Lowe V, Dickson DW, Josephs KA. FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. J Neurol 2014; 261 (04) 710-716
    CrossrefPubMedGoogle Scholar
  • 96 Smith R, Schöll M, Honer M, Nilsson CF, Englund E, Hansson O. Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathol 2017; 133 (01) 149-151
    CrossrefPubMedGoogle Scholar
  • 97 Xia C-F, Arteaga J, Chen G. , et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013; 9 (06) 666-676
    CrossrefPubMedGoogle Scholar
  • 98 Lemoine L, Gillberg P-G, Svedberg M. , et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther 2017; 9 (01) 96
    CrossrefPubMedGoogle Scholar
  • 99 Passamonti L, Vázquez Rodríguez P, Hong YT. , et al. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain 2017; 140 (03) 781-791
    PubMedGoogle Scholar
  • 100 Ono M, Sahara N, Kumata K. , et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 2017; 140 (03) 764-780
    PubMedGoogle Scholar
  • 101 Whitwell JL, Lowe VJ, Tosakulwong N. , et al. [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord 2017; 32 (01) 124-133
    CrossrefPubMedGoogle Scholar
  • 102 Cho H, Choi JY, Hwang MS. , et al. Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord 2017; 32 (01) 134-140
    CrossrefPubMedGoogle Scholar
  • 103 Smith R, Schain M, Nilsson C. , et al. Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord 2017; 32 (01) 108-114
    CrossrefPubMedGoogle Scholar
  • 104 Cho H, Baek MS, Choi JY. , et al. 18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome. Neurology 2017; 89 (11) 1170-1178
    CrossrefPubMedGoogle Scholar
  • 105 Josephs KA, Whitwell JL, Tacik P. , et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 2016; 132 (06) 931-933
    CrossrefPubMedGoogle Scholar
  • 106 McMillan CT, Irwin DJ, Nasrallah I. , et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 2016; 132 (06) 935-937
    CrossrefPubMedGoogle Scholar
  • 107 Lowe VJ, Curran G, Fang P. , et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 2016; 4 (01) 58
    CrossrefPubMedGoogle Scholar
  • 108 Cardoso F. Botulinum toxin in parkinsonism: the when, how, and which for botulinum toxin injections. Toxicon 2018; 147: 107-110
    CrossrefPubMedGoogle Scholar
  • 109 Clerici I, Ferrazzoli D, Maestri R. , et al. Rehabilitation in progressive supranuclear palsy: Effectiveness of two multidisciplinary treatments. PLoS One 2017; 12 (02) e0170927-e0170912
    CrossrefPubMedGoogle Scholar
  • 110 Wiblin L, Lee M, Burn D. Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy. Parkinsonism Relat Disord 2017; 34 (C): 7-14
    CrossrefPubMedGoogle Scholar
  • 111 Marsili L, Suppa A, Berardelli A, Colosimo C. Therapeutic interventions in parkinsonism: corticobasal degeneration. Parkinsonism Relat Disord 2016; 22 (Suppl. 01) S96-S100
    CrossrefPubMedGoogle Scholar
  • 112 Tolosa E, Litvan I, Höglinger GU. , et al; TAUROS Investigators. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 2014; 29 (04) 470-478
    CrossrefPubMedGoogle Scholar
  • 113 Boxer AL, Lang AE, Grossman M. , et al; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014; 13 (07) 676-685
    CrossrefPubMedGoogle Scholar
  • 114 Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. ; NNIPPS Study Group. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009; 132 (Pt 1): 156-171
    CrossrefPubMedGoogle Scholar
  • 115 West T, Hu Y, Verghese PB. , et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies. J Prev Alzheimers Dis 2017; 4 (04) 236-241
    PubMedGoogle Scholar
  • 116 Kondo A, Shahpasand K, Mannix R. , et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 2015; 523 (7561): 431-436
    CrossrefPubMedGoogle Scholar
  • 117 Yanamandra K, Kfoury N, Jiang H. , et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013; 80 (02) 402-414
    CrossrefPubMedGoogle Scholar
  • 118 Mably AJ, Kanmert D, Mc Donald JM. , et al. Tau immunization: a cautionary tale?. Neurobiol Aging 2015; 36 (03) 1316-1332
    CrossrefPubMedGoogle Scholar
  • 119 Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 2014; 76 (02) 185-205
    CrossrefPubMedGoogle Scholar
  • 120 Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying therapies in Alzheimer's disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis 2018; 64 (s1): S3-S22
    CrossrefPubMedGoogle Scholar
  • 121 Marschall AL, Dübel S, Böldicke T. Specific in vivo knockdown of protein function by intrabodies. MAbs 2015; 7 (06) 1010-1035
    CrossrefPubMedGoogle Scholar
  • 122 DeVos SL, Goncharoff DK, Chen G. , et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci 2013; 33 (31) 12887-12897
    CrossrefPubMedGoogle Scholar
  • 123 Sud R, Geller ET, Schellenberg GD. Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol Ther Nucleic Acids 2014; 3: e180-e111
    CrossrefPubMedGoogle Scholar